- Home
- ZLAB
ZLAB
Zai Lab Limited
as 07-26-2024 4:00pm EST
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
| Founded: | 2013 | Country: | China |
| Employees: | N/A | City: | SHANGHAI |
| Market Cap: | 2.0B | IPO Year: | 2017 |
| Target Price: | $56.21 | AVG Volume (30 days): | 505.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.48 - $32.60 | Next Earning Date: | 08-06-2024 |
| Revenue: | $291,071,000 | Revenue Growth: | 25.94% |
| Revenue Growth (this year): | 47.89% | Revenue Growth (next year): | 49.46% |
Stock Insider Trading Activity of Zai Lab Limited (ZLAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lis William | ZLAB | Director | Jul 1 '24 | Sell | $17.31 | 10,297 | $178,281.23 | 53,189 | SEC Form 4 |
| Lis William | ZLAB | Director | Jul 1 '24 | Sell | $18.04 | 100 | $1,804.00 | 53,089 | SEC Form 4 |
| Du Ying | ZLAB | Chairperson & CEO | Jun 28 '24 | Sell | $17.48 | 7,013 | $122,573.21 | 1,081,910 | SEC Form 4 |
| Reinhart Harald | ZLAB | See Remarks | Jun 25 '24 | Sell | $17.90 | 7,431 | $133,022.33 | 62,619 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Jun 25 '24 | Sell | $17.90 | 5,062 | $90,614.86 | 25,946 | SEC Form 4 |
| Du Ying | ZLAB | Chairperson & CEO | Jun 25 '24 | Sell | $17.90 | 23,939 | $428,532.04 | 1,142,833 | SEC Form 4 |
| Chen Yajing | ZLAB | Chief Financial Officer | Jun 25 '24 | Sell | $17.90 | 2,154 | $38,558.75 | 13,714 | SEC Form 4 |
| Smiley Joshua L | ZLAB | See Remarks | May 13 '24 | Buy | $21.40 | 3,000 | $64,200.00 | 31,684 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 3 '24 | Sell | $15.67 | 1,244 | $19,497.21 | 26,408 | SEC Form 4 |
| Smiley Joshua L | ZLAB | See Remarks | Apr 3 '24 | Sell | $15.67 | 1,988 | $31,157.92 | 28,684 | SEC Form 4 |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 3 '24 | Sell | $15.67 | 845 | $13,243.69 | 9,618 | SEC Form 4 |
| Amado Rafael | ZLAB | See Remarks | Apr 3 '24 | Sell | $15.67 | 1,952 | $30,593.70 | 23,532 | SEC Form 4 |
| Reinhart Harald | ZLAB | See Remarks | Apr 3 '24 | Sell | $15.67 | 2,105 | $32,991.67 | 51,800 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 1 '24 | Sell | $16.15 | 675 | $10,901.93 | 22,831 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Apr 1 '24 | Sell | $16.15 | 210 | $3,391.71 | 22,621 | SEC Form 4 |
| Reinhart Harald | ZLAB | See Remarks | Apr 1 '24 | Sell | $16.15 | 1,360 | $21,965.36 | 49,048 | SEC Form 4 |
| Reinhart Harald | ZLAB | See Remarks | Apr 1 '24 | Sell | $16.15 | 413 | $6,670.36 | 48,635 | SEC Form 4 |
| Du Ying | ZLAB | Chairperson & CEO | Apr 1 '24 | Sell | $16.15 | 4,400 | $71,064.40 | 1,109,359 | SEC Form 4 |
| Du Ying | ZLAB | Chairperson & CEO | Apr 1 '24 | Sell | $16.15 | 1,387 | $22,401.44 | 1,107,972 | SEC Form 4 |
| Chen Yajing | ZLAB | Chief Financial Officer | Apr 1 '24 | Sell | $16.15 | 519 | $8,382.37 | 7,963 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Mar 15 '24 | Sell | $18.71 | 10,000 | $187,127.00 | 20,005 | SEC Form 4 |
| Amado Rafael | ZLAB | See Remarks | Mar 15 '24 | Sell | $18.86 | 2,544 | $47,979.84 | 20,093 | SEC Form 4 |
| Smiley Joshua L | ZLAB | See Remarks | Mar 1 '24 | Buy | $20.83 | 3,000 | $62,490.00 | 23,527 | SEC Form 4 |
| Edmondson Frazor Titus III | ZLAB | Chief Legal Officer | Jan 1 '24 | Sell | $26.12 | 4,803 | $125,463.97 | 30,005 | SEC Form 4 |
| Du Ying | ZLAB | Chairperson & CEO | Jan 1 '24 | Sell | $26.12 | 8,380 | $218,902.36 | 1,133,450 | SEC Form 4 |
Latest Zai Lab Limited News
ZLAB Breaking Stock News: Dive into ZLAB Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
10 days ago
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
MT Newswires
11 days ago
Argenx, Zai Lab Get Chinese Regulator's Nod for Subcutaneous Add-on Injection Targeting Eneralized Myasthenia Gravis
Business Wire
11 days ago
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
Business Wire
11 days ago
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
MT Newswires
14 days ago
JPMorgan Cuts Price Target on Zai Lab to $38 From $43, Maintains Overweight Rating
Zacks
16 days ago
Best Momentum Stocks to Buy for July 10th
Business Wire
17 days ago
Zai Lab to Announce Second Quarter 2024 Financial Results and Recent Corporate Updates on August 6, 2024
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 07/01/2024
Compare ZLAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZLAB Zai Lab Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.